If Republicans are looking for ways to rein in costs and restore integrity to the health sector as part of their end-of-year package, they’d do well to set their sights on 340B.
Members of the Senate Health, Education, Labor, and Pensions Committee held a hearing in October to discuss a federal healthcare policy long overdue for reform — the 340B Drug Pricing Program.
Created to expand access to affordable medicines for low-income people, 340B has since fallen victim to rampant abuse by hospitals.
The result has been massive and unsustainable growth in the program — and little help for patients in need.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
340B Drug Pricing Program Overdue for Reform, GOP Can Help
Sally C. Pipes
If Republicans are looking for ways to rein in costs and restore integrity to the health sector as part of their end-of-year package, they’d do well to set their sights on 340B.
Members of the Senate Health, Education, Labor, and Pensions Committee held a hearing in October to discuss a federal healthcare policy long overdue for reform — the 340B Drug Pricing Program.
Created to expand access to affordable medicines for low-income people, 340B has since fallen victim to rampant abuse by hospitals.
The result has been massive and unsustainable growth in the program — and little help for patients in need.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.